TAFI inhibitors (Merck & Co)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameTAFI inhibitors (Merck & Co)
Drug Alias Namethrombin-activatable fibrinolysis inhibitor inhibitors (Merck & Co)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCarboxypeptidase B2 isoform A inhibitors
TargetsCarboxypeptidase B2 isoform A
Therapy Area/IndicationsVenous ThrombosisMyocardial InfarctionAtrial Fibrillation +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsVenous ThrombosisMyocardial InfarctionAtrial Fibrillation +[4] 

Other Information

ATC CodeN/A
Related LinksN/A